New strategies for stem cell mobilization

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 4, Issue 1, 2012, Pages

  Lemoli, Roberto M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLACEBO; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANEMIA; ARTICLE; BONE MARROW; BONE PAIN; CANCER CHEMOTHERAPY; CANCER PATIENT; CD34 SELECTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEMATOPOIETIC STEM CELL; HUMAN; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; STEM CELL MOBILIZATION; THROMBOCYTE COUNT;

EID: 84875032377     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2012.066     Document Type: Article

References (56)

1. Gratwohl A, Baldomero H, Schwendener A, et al. The EBMT acitivity survey 2008: impact of team size, team density and new trends. Bone Marrow Transplant 2011; 46: 174-91. http://dx.doi.org/10.1038/bmt.2010.69 PMid:20348970
2. Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34(+) cells reinfused predict engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 967-72. http://dx.doi.org/10.1038/sj.bmt.1703575 PMid:12098064
3. Bensinger W, DiPersio JF, MacCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009; 43: 181-95. http://dx.doi.org/10.1038/bmt.2008.410 PMid:19139734
4. Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010; 150: 647-62. http://dx.doi.org/10.1111/j.1365-2141.2010.08313.x PMid:20636438
5. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother. 1992; 1: 329-41. http://dx.doi.org/10.1089/scd.1.1992.1.329 PMid:1285382
6. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplantation for multiple myeloma: identification of favourable variables for engraftment in 225 patients. Blood. 1995; 85: 588-96. PMid:7529066
7. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-77. PMid:10715309
8. Blystad AK, Delabie J, Kvaloy S, et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large Bcell lymphoma and follicular lymphoma grade 3 treated with highdose therapy. Br J Haematol 2004; 125: 605-12. http://dx.doi.org/10.1111/j.1365-2141.2004.04951.x PMid:15147376
9. Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84-92. http://dx.doi.org/10.1053/bbmt.1998.v4.pm9763111 PMid:9763111
10. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-58. PMid:9116266
11. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilizaton strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-56. http://dx.doi.org/10.1016/j.bbmt.2008.07.004 PMid:18721768
12. Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic stem cells - definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490-99. http://dx.doi.org/10.1016/j.bbmt.2009.11.012 PMid:19925876
13. Cottler-Fox MH, Lapidot T, Petit I, et al. Stem cell mobilization. Hematology. Am Soc Hematol Educ Program. 2003;419-37. http://dx.doi.org/10.1182/asheducation-2003.1.419
14. Tigue CC, McKoy JM, Evens AM, et al. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007;40:185-92. http://dx.doi.org/10.1038/sj.bmt.1705722 PMid:17563736
15. LeBlanc R, Roy J, Vu L, Cantin G. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone marrow Transplant 1999; 23: 991-6. http://dx.doi.org/10.1038/sj.bmt.1701756 PMid:10373063
16. Isidori A, Tani M, Bonifazi F, et al. Phase II study of a single Pegfilgrastim injection as adjunct to chemotherapy to mobilize stem cells into peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90: 225-31. PMid:15710576
17. Russell NH, Mesters R, Schubert J, et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008; 93:405-12. http://dx.doi.org/10.3324/haematol.11287 PMid:18268285
18. Rutella S, Bonanno G, Pierelli L, et al. Granulocyte colonystimulating factor promotes the generation of regulatory DCs through induction of IL-10 and IFN-a. Eur J Immunol 2004; 34: 1291-1302. http://dx.doi.org/10.1002/eji.200324651 PMid:15114662
19. Moskowitz CH, Glassman JR, Wuest D, et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998;4:311-6. PMid:9516916
20. Fitoussi O, Perreau V, Boiron JM, et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27:837-42. http://dx.doi.org/10.1038/sj.bmt.1702879 PMid:11477441
21. Perseghin P, Terruzzi E, Dassi M, et al. Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci 2009; 41: 33-7. http://dx.doi.org/10.1016/j.transci.2009.05.011 PMid:19540167
22. Bonig H, Papayannopoulou T. Mobilization of hematopoietic stem/progenitor cells: general principles and molecular mechanisms. Methods Mol Bio 2012; 904: 1-14. PMid:22890918
23. Körbling M. Mobilization regimens for harvesting autologous and allogeneic peripheral blood stem cells. In: Atkinson K, Fibbe WE, Champlin R, Ljungman P, Ritz J, Brenner MK, eds. Clinical Bone Marrow and Blood Stem Cell Transplantation. 3rd Ed. Cambridge, UK: Cambridge University Press 2004:383-403.
24. Jantunen E, Kvalheim G. Mobilization strategies in hard-tomobilize patients with lymphoid malignancies. Eur J Haematol. 2010; 85: 463-71. http://dx.doi.org/10.1111/j.1600-0609.2010.01520.x PMid:20738393
25. Olivieri A, Marchetti M, Lemoli RM, et al. on behalf of the Italian Group for Stem Cell Transplantation (GITMO) Proposed definition of "poor mobilizer" in lymphoma and multiple myeloma: An analytic hierarchy process by an ad-hoc Working Group Gruppo ItalianoTrapianto di Midollo Osseo (GITMO). Bone Marrow Transplantation 2012; 47: 342-51. http://dx.doi.org/10.1038/bmt.2011.82 PMid:21625224 PMCid:3296914
26. Fruehauf S, Haas R, Conradt C, et al. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuGCSF)-supported cytotoxic chemotherapy. Blood 1995; 85: 2619-26 PMid:7537123
27. Fruehauf S, Schmitt K, Veldwijk MR, et al. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol 1999; 105: 786-94. http://dx.doi.org/10.1046/j.1365-2141.1999.01405.x PMid:10354148
28. Pettengell R, Morgenstern GR, Woll PJ, et al. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993; 82: 3770-7.
29. Schots R, Van Riet I, Damiaens S, et al. The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis. Bone Marrow Transplant. 1996; 17: 509-15. PMid:8722347
30. Fu P, Bagai RK, Meyerson H, et al. Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization. Bone Marrow Transplant 2006; 38: 189-96. http://dx.doi.org/10.1038/sj.bmt.1705431 PMid:16850032
31. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-77. PMid:10715309
32. Rossi L, Salvestrini V, Ferrari D, Di Virgilio F, Lemoli RM. The sixth sense: Hematopoietic Stem Cells detect danger through purinergic signalling. Blood 2012, July, 1 Epub ahed of print
33. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999; 283: 845-48 http://dx.doi.org/10.1126/science.283.5403.845 PMid:9933168
34. Lemoli R, d'Addio A. Hematopoietic stem cell mobilization. Haematologica 2008; 93: 321-24. http://dx.doi.org/10.3324/haematol.12616 PMid:18310535
35. Hübel K, Liles WC, Broxmeyer HE, et al. Leucocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther. 2004; 1: 165-72. http://dx.doi.org/10.3816/SCT.2004.n.008 PMid:18628138
36. To LB, Haylock DN, Simmons PJ, et al. The biology and clinical uses of blood stem cells. Blood. 1997; 89:2233-58. Review. PMid:9116266
37. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol. 2004; 22: 1095-102. http://dx.doi.org/10.1200/JCO.2004.07.131 PMid:15020611
38. Flomenberg N, Devine SM, DiPersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-74. http://dx.doi.org/10.1182/blood-2005-02-0468 PMid:15890685
39. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2008; 41: 331-38. http://dx.doi.org/10.1038/sj.bmt.1705908 PMid:17994119
40. Duarte RF, Shaw BE, Marin P, et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011; 46:52-8. http://dx.doi.org/10.1038/bmt.2010.54 PMid:20305700
41. DiPersio JF, Stadtmayer EA, Nademanee A, et al. for the 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009; 113: 5720-26. PMid:19363221
42. DiPersio JF, Micallef I, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009; 27: 4767-73. http://dx.doi.org/10.1200/JCO.2008.20.7209 PMid:19720922
43. Maziarz RT, Micallef IN, Stiff P, et al. Plerixafor plus G-CSF is an effective regimen to mobilize hematopoietic stem cells in NHL patients with circulating peripheral blood CD34+ cells/μl < 10. Blood. 2009; 114 (S); 19.
44. Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010; 45: 39-47. http://dx.doi.org/10.1038/bmt.2009.119 PMid:19483760
45. Jantunen E, Penttilä K, Pyörälä M, et al. Addition of plerixafor to a chemotherapy and G-CSF mobilization in hard-to-mobilize patients. Bone Marrow Transplant 2011; 46:308-9. http://dx.doi.org/10.1038/bmt.2010.93 PMid:20400986
46. D'Addio A, Curti A, Worel N, et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and GCSF. Bone Marrow Transplant 2011; 46: 356-63. http://dx.doi.org/10.1038/bmt.2010.128 PMid:20577218
47. Josefsen D, Rechnitzer C, Parto K, et al. The use of plerixafor for blood stem mobilization reduces the frequency of mobilization failure in patients planned to undergo autologous stem cell transplantation. Eur Haematol. 2010; 4: 24-9.
48. Hubel K, Fresen MM, Salwender H, et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant. 2011; 46: 1045-52. http://dx.doi.org/10.1038/bmt.2010.249 PMid:20972470
49. Fruehauf S, Veldvijk MR, Seeger T, et al. A combination of granulocyte colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than GCSF alone: results of a European phase II study. Cytotherapy 2009; 11: 992-1001. http://dx.doi.org/10.3109/14653240903121245 PMid:19929463
50. Fruehauf S, Tricot G. Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplant outcomes. Biol Blood Marrow Transplant. 2010; 16: 1629-48. http://dx.doi.org/10.1016/j.bbmt.2010.02.002 PMid:20144908
51. Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010; 45: 63-8. http://dx.doi.org/10.1038/bmt.2009.130 PMid:19543330
52. Fruehauf S, Ehninger G, Hubel K, et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and GCSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2010; 45: 269-75. http://dx.doi.org/10.1038/bmt.2009.142 PMid:19597422
53. Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012;119: 3917-24. http://dx.doi.org/10.1182/blood-2011-10-383406 PMid:22308295
54. Jantunen E, Lemoli RM. Pre-emptive use of Plerixafor in hard-tomobilize patients: An emerging concept. Transfusion 2012; 52: 906-14. http://dx.doi.org/10.1111/j.1537-2995.2011.03349.x PMid:21981351
55. Costa LJ, Alexander ET, Hogan KR, et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46:64-69. http://dx.doi.org/10.1038/bmt.2010.78 PMid:20383210
56. Costa LJ, Milles AN, Alexander ET, et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant. 2011; 46: 523-8. http://dx.doi.org/10.1038/bmt.2010.170 PMid:20622909